[Comparative study on dendritic cells stimulated with HBsAg or HBcAg in patients with chronic hepatitis B]

Peng Kang1, Shu-Lan Luo, Shu-Chen Li

  • 1Department of Infectious Diseases, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.

Insights

Hepatitis B core antigen (HBcAg) more effectively activates dendritic cells (DCs) than hepatitis B surface antigen (HBsAg). This enhanced DC activation by HBcAg leads to a stronger T cell immune response in chronic hepatitis B patients.

Area of Science:

  • Immunology
  • Hepatology
  • Cell Biology

Background:

  • Chronic hepatitis B (CHB) is a significant global health concern.
  • Dendritic cells (DCs) play a crucial role in initiating adaptive immune responses.
  • Understanding DC activation by hepatitis B virus (HBV) antigens is key to developing effective immunotherapies.

Purpose of the Study:

  • To investigate the differential activation of dendritic cells (DCs) by hepatitis B core antigen (HBcAg) and hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B.
  • To evaluate the impact of antigen stimulation on DC maturation markers, T lymphocyte proliferation, and interleukin-12 production.

Main Methods:

  • Dendritic cells were isolated from peripheral blood monocytes of CHB patients.
  • DCs were stimulated with either HBsAg or HBcAg.
  • Flow cytometry was used to analyze DC surface molecule expression (CD86).
  • T lymphocyte proliferation was assessed using a liquid scintillation counter.
  • Interleukin-12 (IL-12) levels in mixed lymphocyte reactions (MLRs) were measured by ELISA.

Main Results:

  • HBeAg stimulation significantly increased the expression rate of the DC activation marker CD86 compared to HBsAg stimulation and controls.
  • DCs loaded with HBcAg demonstrated a significantly higher capacity to induce T lymphocyte proliferation than those loaded with HBsAg.
  • The production of IL-12 in MLRs was significantly elevated when DCs were stimulated with HBcAg compared to HBsAg.

Conclusions:

  • Hepatitis B core antigen (HBcAg) is a more potent stimulator of dendritic cell activation compared to hepatitis B surface antigen (HBsAg) in the context of chronic hepatitis B.
  • HBcAg-stimulated DCs exhibit enhanced antigen-presenting capabilities, leading to a more robust specific T cell immune response.
  • These findings suggest that HBcAg may hold therapeutic potential for enhancing immune responses against chronic hepatitis B.
Abstract